Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02AYX
|
|||
| Former ID |
DNC010279
|
|||
| Drug Name |
2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione
|
|||
| Synonyms |
CHEMBL611665; 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H6N2O3
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C=C3C(=O)NC(=O)N=C3O2
|
|||
| InChI |
1S/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)
|
|||
| InChIKey |
BFMCRAXOACCPEL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NAD-dependent deacetylase sirtuin-1 (SIRT1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | FoxO signaling pathway | |||
| AMPK signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Amphetamine addiction | ||||
| MicroRNAs in cancer | ||||
| Panther Pathway | p53 pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| Signaling events mediated by HDAC Class III | ||||
| E2F transcription factor network | ||||
| HIF-2-alpha transcription factor network | ||||
| Signaling events mediated by HDAC Class I | ||||
| FoxO family signaling | ||||
| Regulation of Androgen receptor activity | ||||
| Regulation of retinoblastoma protein | ||||
| Reactome | RORA activates gene expression | |||
| Regulation of HSF1-mediated heat shock response | ||||
| Circadian Clock | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.